Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with bipolar disorder. Asenapine also belongs to the dibenzo-oxepino pyrrole class. It is also for severe post-traumatic stress disorder nightmares in soldiers as ...
适用于成人精神分裂症和双相情感障碍患者的治疗。
Christophe G Lambert, Albuquerque, New Mexico, United States
Clinique Notre-Dame des Victoires, Quebec, Canada
Woodland International Research Group, Inc., Little Rock, Arkansas, United States
Collaborative Neuroscience Network, LLC, Garden Grove, California, United States
Clinical Innovations, Inc, Costa Mesa, California, United States
University of Cincinnati, Cincinnati, Ohio, United States
University of California Irvine Medical Center, Orange, California, United States
Forest Investigative Site 2001, Austin, Texas, United States
University Hospitals Case Medical Center, Cleveland, Ohio, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.